Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 3
2009 2
2010 4
2011 1
2012 3
2013 4
2014 2
2018 1
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
CYP2C19 variation and citalopram response.
Mrazek DA, Biernacka JM, O'Kane DJ, Black JL, Cunningham JM, Drews MS, Snyder KA, Stevens SR, Rush AJ, Weinshilboum RM. Mrazek DA, et al. Pharmacogenet Genomics. 2011 Jan;21(1):1-9. doi: 10.1097/fpc.0b013e328340bc5a. Pharmacogenet Genomics. 2011. PMID: 21192344 Free PMC article. Clinical Trial.
DISC1-TSNAX and DAOA genes in major depression and citalopram efficacy.
Arias B, Fabbri C, Serretti A, Drago A, Mitjans M, Gastó C, Catalán R, Fañanás L. Arias B, et al. J Affect Disord. 2014 Oct;168:91-7. doi: 10.1016/j.jad.2014.06.048. Epub 2014 Jul 5. J Affect Disord. 2014. PMID: 25043320
In the STAR(*)D a cluster of SNPs from 20 to 40Kbp from DISC1 findings in the original sample was associated with citalopram response, as well as rs778330 (12,325bp from rs778294). LIMITATIONS: Relatively small size of the original sample and focus on only three can …
In the STAR(*)D a cluster of SNPs from 20 to 40Kbp from DISC1 findings in the original sample was associated with citalopram respo …
Inclusion of genetic variants in an ensemble of gradient boosting decision trees does not improve the prediction of citalopram treatment response.
Shumake J, Mallard TT, McGeary JE, Beevers CG. Shumake J, et al. Sci Rep. 2021 Feb 12;11(1):3780. doi: 10.1038/s41598-021-83338-2. Sci Rep. 2021. PMID: 33580158 Free PMC article.
Using pre-treatment clinical and symptom predictors only, out-of-fold prediction of a novel treatment response definition based on STAR*D treatment guidelines was acceptable, AUC = .659, 95% CI [0.629, 0.689]. ...In the current study, incorporating SNP variation into progn …
Using pre-treatment clinical and symptom predictors only, out-of-fold prediction of a novel treatment response definition based on ST …
Prognostic subgroups for citalopram response in the STAR*D trial.
Jakubovski E, Bloch MH. Jakubovski E, et al. J Clin Psychiatry. 2014 Jul;75(7):738-47. doi: 10.4088/JCP.13m08727. J Clin Psychiatry. 2014. PMID: 24912106 Free PMC article. Clinical Trial.

Among baseline clinical characteristics, employment status (N = 2,477; chi21 = 78.1; P < .001) and income level (N = 2,512; chi21 = 77.7; P < .001) were the most informative in predicting treatment outcome. ...This finding implies that socioeconomic factors may be mo

…

Among baseline clinical characteristics, employment status (N = 2,477; chi21 = 78.1; P < .001) and income level (N = 2,512; chi21

…
TPH1, MAOA, serotonin receptor 2A and 2C genes in citalopram response: possible effect in melancholic and psychotic depression.
Arias B, Fabbri C, Gressier F, Serretti A, Mitjans M, Gastó C, Catalán R, De Ronchi D, Fañanás L. Arias B, et al. Neuropsychobiology. 2013;67(1):41-7. doi: 10.1159/000343388. Epub 2012 Dec 4. Neuropsychobiology. 2013. PMID: 23221997
The effect of these polymorphisms was tested both in the whole sample and in depressive subtypes with usually higher clinical severity: psychotic and melancholic MDD. RESULTS: No effect on response, remission and symptom improvement was found for the four polymorphisms. .. …
The effect of these polymorphisms was tested both in the whole sample and in depressive subtypes with usually higher clinical severit …
Race, genetic ancestry and response to antidepressant treatment for major depression.
Murphy E, Hou L, Maher BS, Woldehawariat G, Kassem L, Akula N, Laje G, McMahon FJ. Murphy E, et al. Neuropsychopharmacology. 2013 Dec;38(13):2598-606. doi: 10.1038/npp.2013.166. Epub 2013 Jul 5. Neuropsychopharmacology. 2013. PMID: 23827886 Free PMC article.
This racial disparity persisted even after socioeconomic and baseline clinical factors were taken into account. Some studies have suggested genetic contributions to this disparity, but none have attempted to disentangle race and genetic ancestry. Here we used genome-wide s …
This racial disparity persisted even after socioeconomic and baseline clinical factors were taken into account. Some studies have sug …
Association of mu-opioid receptor variants and response to citalopram treatment in major depressive disorder.
Garriock HA, Tanowitz M, Kraft JB, Dang VC, Peters EJ, Jenkins GD, Reinalda MS, McGrath PJ, von Zastrow M, Slager SL, Hamilton SP. Garriock HA, et al. Am J Psychiatry. 2010 May;167(5):565-73. doi: 10.1176/appi.ajp.2009.08081167. Epub 2010 Mar 1. Am J Psychiatry. 2010. PMID: 20194481 Free PMC article.
OBJECTIVE: Because previous preclinical and clinical studies have implicated the endogenous opioid system in major depression and in the neurochemical action of antidepressants, the authors examined how DNA variation in the mu-opioid receptor gene may influence population …
OBJECTIVE: Because previous preclinical and clinical studies have implicated the endogenous opioid system in major depression and in …
SLC6A4 variation and citalopram response.
Mrazek DA, Rush AJ, Biernacka JM, O'Kane DJ, Cunningham JM, Wieben ED, Schaid DJ, Drews MS, Courson VL, Snyder KA, Black JL 3rd, Weinshilboum RM. Mrazek DA, et al. Am J Med Genet B Neuropsychiatr Genet. 2009 Apr 5;150B(3):341-51. doi: 10.1002/ajmg.b.30816. Am J Med Genet B Neuropsychiatr Genet. 2009. PMID: 18618621 Free PMC article.
Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample.
Peters EJ, Slager SL, Kraft JB, Jenkins GD, Reinalda MS, McGrath PJ, Hamilton SP. Peters EJ, et al. PLoS One. 2008 Apr 2;3(4):e1872. doi: 10.1371/journal.pone.0001872. PLoS One. 2008. PMID: 18382661 Free PMC article.
We examined the associations between these polymorphisms and citalopram response and tolerance. Significant associations were validated in the second stage for those polymorphism found to be statistically significant in the first stage. ...For managing pharmacologic …
We examined the associations between these polymorphisms and citalopram response and tolerance. Significant associations were …
18 results